Not for distribution to U.S. news wire services or dissemination in the
Ticker: TSX - TOS
Shares Outstanding: 65,888,182
QUÉBEC CITY, Feb. 25, 2013 /CNW Telbec/ - TSO3 Inc. ("TSO3" or the "Company") (TSX: TOS) an innovator in sterilization technology
for medical devices in healthcare settings, is pleased to announce that
it has filed a final short form prospectus with the securities
regulatory authorities in all provinces of Canada with respect to a
previously announced public offering of 7,000,000 common shares (the
"Common Shares") at the price of CDN $1.00 per Common Share (the "Issue
Price") for aggregate gross proceeds to TSO3 of CDN $7,000,000 (the "Offering").
The offering is being made on a bought deal basis through a syndicate of
underwriters co-led by Desjardins Securities Inc. and Canaccord Genuity
Corp. and including Byron Capital Markets Ltd. and Laurentian Bank
Securities Inc. (collectively, the "Underwriters"). The Offering is
expected to close on or about March 4, 2013 and is subject to customary
conditions and regulatory approvals.
The Company has granted the Underwriters an over-allotment option,
exercisable for a period of 30 days following the closing of the
Offering, to purchase up to an additional 15% of the number of common
shares issued from treasury pursuant to the Offering, at the Issue
As the Company actively pursues US regulatory clearance for the
STERIZONE® 125L+ Sterilizer, net proceeds from the Offering will be
used to strengthen the Company's financial position in negotiating a
channel partner agreement. The proceeds will also allow for continued
new product development.
The Toronto Stock Exchange (the "TSX") has conditionally approved the
listing of the Common Shares, subject to TSO3 fulfilling all of the listing requirements of the TSX on or before May
This news release is not an offer of securities for sale in the United
States and is not an offer to sell or solicitation of an offer to buy
any securities of the Company, nor shall it form the basis of, or be
relied upon in connection with any contract for purchase or
subscription. Securities may not be offered or sold in the United
States absent registration under the U.S. Securities Act of 1933 (the "Securities Act") or an exemption from registration thereunder.
These securities have not been and will not be registered under the
Securities Act or the securities laws of any state and may not be
offered or sold in the United States absent registration under the
Securities Act and applicable state securities laws or pursuant to an
applicable exemption therefrom.
TSO3, founded in Québec City in 1998, specializes in the research and
development of innovative, high-performance medical instrument
sterilization technology with high commercial potential. TSO3 designs products for sterile processing areas in the hospital
environment and offers an advantageous replacement solutions to other
low temperature sterilization processes currently used in hospitals.
For more information about TSO3, visit the Company's Web site at www.tso3.com
The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical
facts (including, without limitation, those regarding the timing or
outcome of any financing undertaken by TSO3) are forward-looking
statements that involve certain risks, uncertainties and hypotheses,
including, but not limited to, general business and economic
conditions, the condition of the financial markets, the ability of TSO3
to obtain financing on favourable terms and other risks and
SOURCE: TSO3 Inc.
For further information:
Director - Investor and Business Relations
(418) 651-0003, Ext. 237